• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ORIC

ORIC

ORIC Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD7.84

+0.22 (+2.89%)

Rating:C-

Company Profile

CEO

Jacob Chacko

IPO Date

2020-04-24

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$7.58

Prev. Close

$7.62

Day Low

$7.32

Day High

$7.90

52W Low

$7.23

52W High

$14.93

Market Cap

$0.81B

Volume

2.28M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

25.6%

Avg Negative

1.8%

Avg Neutral

72.8%

News Feed

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

GlobeNewsWire·6/2/2021·↑ positive

ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/26/2021·↑ positive

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewsWire·4/12/2021·↑ positive

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

GlobeNewsWire·3/23/2021·↑ positive

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewsWire·3/10/2021·↑ positive

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire·2/3/2021·↑ positive

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

GlobeNewsWire·1/11/2021·↑ positive

ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1/4/2021·↑ positive

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

GlobeNewsWire·12/21/2020·↑ positive

The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger

benzinga·10/20/2020·↑ positive